JOP20220235A1 - 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52 - Google Patents

3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52

Info

Publication number
JOP20220235A1
JOP20220235A1 JOJO/P/2022/0235A JOP20220235A JOP20220235A1 JO P20220235 A1 JOP20220235 A1 JO P20220235A1 JO P20220235 A JOP20220235 A JO P20220235A JO P20220235 A1 JOP20220235 A1 JO P20220235A1
Authority
JO
Jordan
Prior art keywords
substituted
gpr52
phenoxyazetidin
pyrazines
phenoxyazitidine
Prior art date
Application number
JOJO/P/2022/0235A
Other languages
Arabic (ar)
English (en)
Inventor
Barbara Bertani
Kai Gerlach
Frank Runge
Graeme Semple
Yifeng Xiong
Giacomo Fossati
Marco Ferrara
Uta Friederike Lessel
Ursula Mueller-Vieira
Scott Hobson
Julian Wippich
Original Assignee
Arena Pharm Inc
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Boehringer Ingelheim Int filed Critical Arena Pharm Inc
Publication of JOP20220235A1 publication Critical patent/JOP20220235A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JOJO/P/2022/0235A 2020-03-30 2022-09-28 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52 JOP20220235A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
JOP20220235A1 true JOP20220235A1 (ar) 2022-09-28

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2022/0235A JOP20220235A1 (ar) 2020-03-30 2022-09-28 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52

Country Status (20)

Country Link
US (1) US11780827B2 (https=)
EP (1) EP4126850B1 (https=)
JP (1) JP7617134B2 (https=)
KR (1) KR20220161454A (https=)
CN (1) CN115697997B (https=)
AR (1) AR121675A1 (https=)
AU (1) AU2021250303A1 (https=)
BR (1) BR112022018996A2 (https=)
CA (1) CA3176265A1 (https=)
CO (1) CO2022014886A2 (https=)
CR (1) CR20220554A (https=)
DO (1) DOP2022000203A (https=)
EC (1) ECSP22080683A (https=)
IL (1) IL296823A (https=)
JO (1) JOP20220235A1 (https=)
MX (1) MX2022012067A (https=)
PE (1) PE20221918A1 (https=)
PH (1) PH12022552553A1 (https=)
TW (1) TW202204343A (https=)
WO (1) WO2021198149A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2055500A (en) * 1998-12-23 2000-07-31 Eli Lilly And Company Aromatic amides
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
WO2011078360A1 (ja) * 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) * 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) * 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
KR20180004193A (ko) * 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
CA3176265A1 (en) 2021-10-07
EP4126850B1 (en) 2024-04-17
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
IL296823A (en) 2022-11-01
US20220356172A1 (en) 2022-11-10
JP7617134B2 (ja) 2025-01-17
CR20220554A (es) 2023-01-09
KR20220161454A (ko) 2022-12-06
WO2021198149A1 (en) 2021-10-07
US11780827B2 (en) 2023-10-10
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
BR112022018996A2 (pt) 2022-11-01
CO2022014886A2 (es) 2022-10-31
ECSP22080683A (es) 2022-11-30
AR121675A1 (es) 2022-06-29
CN115697997B (zh) 2024-07-30
TW202204343A (zh) 2022-02-01
PE20221918A1 (es) 2022-12-29
JP2023522307A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
JOP20220235A1 (ar) 3-فينوكسي أزيتيدين-1-يل بيرازينات مستبدلة لديها نشاط ناهض لـ gpr52
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
JOP20220267A1 (ar) مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة
JOP20230316B1 (ar) N-(هيدروكسي ألكيل أريل (غير متجانس)) تترا هيدروفيوران كربوكساميدات كمعدلات لقنوات الصوديوم
JOP20220332A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
PH12022553019A1 (en) Il-17a modulators
PH12022500021A1 (en) Il-17a modulators
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX384072B (es) Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa.
MX2021007142A (es) Compuestos organicos.
ZA202309001B (en) Abhd6 antagonist
JOP20240262A1 (ar) المركبات المحتوية على البورون العطري ونظائر الأنسولين ذات الصلة
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
MX2021009082A (es) Compuestos quimicos.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.
PT1682162E (pt) Utilização de opuntia para a produção de um medicamento para o tratamento da depressão
MX385289B (es) Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk).
GEAP202416375A (en) Pro drugs of pde10 compounds